Published in Br J Pharmacol on May 01, 1995
Grapefruit juice-drug interactions. Br J Clin Pharmacol (1998) 2.68
Selective open-channel block of Shaker (Kv1) potassium channels by s-nitrosodithiothreitol (SNDTT). J Gen Physiol (2001) 0.96
Inhibition of HERG potassium channels by the antimalarial agent halofantrine. Br J Pharmacol (2000) 0.89
Bertosamil blocks HERG potassium channels in their open and inactivated states. Br J Pharmacol (2002) 0.81
Mechanisms of block of a human cloned potassium channel by the enantiomers of a new bradycardic agent: S-16257-2 and S-16260-2. Br J Pharmacol (1996) 0.80
PLCδ1 protein rescues ischemia-reperfused heart by the regulation of calcium homeostasis. Mol Ther (2014) 0.77
Ionic blockage of sodium channels in nerve. J Gen Physiol (1973) 20.47
Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol (1990) 6.73
Torsades de pointes occurring in association with terfenadine use. JAMA (1990) 3.93
Mechanism of the cardiotoxic actions of terfenadine. JAMA (1993) 3.27
The internal quaternary ammonium receptor site of Shaker potassium channels. Neuron (1993) 3.15
Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA (1993) 2.78
Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. Circ Res (1993) 2.71
A rapidly activating and slowly inactivating potassium channel cloned from human heart. Functional analysis after stable mammalian cell culture expression. J Gen Physiol (1993) 1.93
Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel. Mol Pharmacol (1992) 1.85
Molecular cloning and characterization of two voltage-gated K+ channel cDNAs from human ventricle. FASEB J (1991) 1.71
Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther (1992) 1.68
Cardiotoxic effect with convulsions in terfenadine overdose. BMJ (1989) 1.65
Block of delayed rectifier potassium current, IK, by flecainide and E-4031 in cat ventricular myocytes. Circulation (1990) 1.38
Suppression of time-dependent outward current in guinea pig ventricular myocytes. Actions of quinidine and amiodarone. Circ Res (1991) 1.34
Age-related appearance of outward currents may contribute to developmental differences in ventricular repolarization. Circ Res (1992) 1.33
Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. J Pharmacol Exp Ther (1985) 1.24
Control of cardiac arrhythmias by selective lengthening of repolarization: theoretic considerations and clinical observations. Am Heart J (1985) 1.22
Torsades de pointes after terfenadine-itraconazole interaction. BMJ (1993) 1.10
Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart. Mol Pharmacol (1993) 1.09
A novel type of depolarization-activated K+ current in isolated adult rat atrial myocytes. Am J Physiol (1991) 1.07
Torsades de pointes occurring in association with terfenadine use. JAMA (1991) 1.03
Understanding consequences of concurrent therapies. JAMA (1993) 0.96
Determination of terfenadine and terfenadine acid metabolite in plasma using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. J Chromatogr (1991) 0.94
Terfenadine. An updated review of its pharmacological properties and therapeutic efficacy. Drugs (1990) 0.91
Electrophysiological effects of the optical isomers of disopyramide and quinidine in the dog. Dependence on stereochemistry. Circ Res (1981) 0.87
Time- and voltage-dependent block of the delayed K+ current by quinidine in rabbit sinoatrial and atrioventricular nodes. J Pharmacol Exp Ther (1989) 0.85
Toxicological findings in a death involving dextromethorphan and terfenadine. Am J Forensic Med Pathol (1992) 0.83
Drug interaction of terfenadine and carbamazepine. Ann Intern Med (1993) 0.78
Single-nucleon pickup spectroscopic factors for levels in 30Si and 30P and the D state of three-nucleon systems. Phys Rev C Nucl Phys (1988) 0.77
Enantiomeric analysis of terfenadine in rat plasma by HPLC. Chirality (1991) 0.77
Potential interaction between terfenadine and macrolide antibiotics. Clin Pharm (1992) 0.77
Direct enantiomeric separation of terfenadine and its major acid metabolite by high-performance liquid chromatography, and the lack of stereoselective terfenadine enantiomer biotransformation in man. J Chromatogr (1991) 0.76
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther (2012) 4.05
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest (1998) 3.66
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther (2011) 3.53
Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin Pharmacol Ther (2011) 3.50
Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther (2012) 3.16
Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol (1998) 3.13
Urea protects Helicobacter (Campylobacter) pylori from the bactericidal effect of acid. Gastroenterology (1990) 3.04
The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther (2011) 2.93
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther (2012) 2.90
AGA technical review on the evaluation and management of occult and obscure gastrointestinal bleeding. Gastroenterology (2000) 2.78
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther (2013) 2.73
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther (2011) 2.36
A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A (2000) 2.26
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res (1999) 2.24
Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation (1990) 2.22
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
The long QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol (2000) 2.06
Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation (1996) 2.04
Molecular analysis of a binding site for quinidine in a human cardiac delayed rectifier K+ channel. Role of S6 in antiarrhythmic drug binding. Circ Res (1996) 2.03
Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Circulation (1999) 2.01
Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. Circulation (1995) 1.75
Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J (1986) 1.74
Global parameter optimization for cardiac potassium channel gating models. Biophys J (1990) 1.72
Molecular cloning and characterization of two voltage-gated K+ channel cDNAs from human ventricle. FASEB J (1991) 1.71
Rapid inactivation determines the rectification and [K+]o dependence of the rapid component of the delayed rectifier K+ current in cardiac cells. Circ Res (1997) 1.61
Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation. J Am Coll Cardiol (2001) 1.60
Cisapride-induced torsades de pointes. J Cardiovasc Electrophysiol (1998) 1.60
Obligatory heterotetramerization of three previously uncharacterized Kv channel alpha-subunits identified in the human genome. Proc Natl Acad Sci U S A (2002) 1.59
Replacement by homologous recombination of the minK gene with lacZ reveals restriction of minK expression to the mouse cardiac conduction system. Circ Res (1999) 1.55
Potential antidiabetics. 8. 4-Arylhydrazono-N'-guanylnitrate-3-methyl-2-pyrazolin-5-ones, 4-arylazo-N'-guanylnitrate-3,5-dimethylpyrazoles, and 4-arylazo-N'-guanylnitrate-3,5-diphenylpyrazoles. J Pharm Sci (1971) 1.54
Sympathetic activation enhances QT prolongation by quinidine. J Cardiovasc Electrophysiol (2001) 1.45
Congenital and acquired long QT syndrome. Eur Heart J (2000) 1.45
Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. Circulation (1999) 1.44
Electrophysiological and pharmacological correspondence between Kv4.2 current and rat cardiac transient outward current. Cardiovasc Res (1997) 1.42
Heteromultimeric assembly of human potassium channels. Molecular basis of a transient outward current? Circ Res (1993) 1.41
Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel. Circulation (1999) 1.40
Functional differences in Kv1.5 currents expressed in mammalian cell lines are due to the presence of endogenous Kv beta 2.1 subunits. J Biol Chem (1996) 1.40
Strategies for personalized medicine-based research and implementation in the clinical workflow. Clin Pharmacol Ther (2012) 1.40
Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length. Circ Res (1985) 1.39
Suppression of time-dependent outward current in guinea pig ventricular myocytes. Actions of quinidine and amiodarone. Circ Res (1991) 1.34
Stereoselective block of cardiac sodium channels by bupivacaine in guinea pig ventricular myocytes. Circulation (1995) 1.32
Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation (1997) 1.31
Acute gastrointestinal bleeding. Med Clin North Am (2000) 1.30
Virtual cathode effects during stimulation of cardiac muscle. Two-dimensional in vivo experiments. Circ Res (1991) 1.30
Time-dependent outward current in guinea pig ventricular myocytes. Gating kinetics of the delayed rectifier. J Gen Physiol (1990) 1.29
Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the european society of cardiology. Eur Heart J (1999) 1.29
Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. Am J Cardiol (1981) 1.28
Acute lower intestinal bleeding. Part II: etiology, therapy, and outcomes. Gastrointest Endosc (1999) 1.27
Classification of deaths after myocardial infarction as arrhythmic or nonarrhythmic (the Cardiac Arrhythmia Pilot Study). Am J Cardiol (1989) 1.27
Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation (1987) 1.22
Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes. Circulation (2001) 1.22
Acute lower intestinal bleeding: part I: clinical presentation and diagnosis. Gastrointest Endosc (1998) 1.21
Clopidogrel: a case for indication-specific pharmacogenetics. Clin Pharmacol Ther (2012) 1.20
Calmodulin kinase inhibition prevents development of the arrhythmogenic transient inward current. Circ Res (1999) 1.19
Drug therapy. Flecainide. N Engl J Med (1986) 1.19
The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther (2012) 1.19
Propafenone. N Engl J Med (1990) 1.17
A K+ channel splice variant common in human heart lacks a C-terminal domain required for expression of rapidly activating delayed rectifier current. J Biol Chem (1998) 1.16
Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther (2001) 1.15
Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers. Biophys J (1995) 1.14
Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III. Circulation (1999) 1.11
Topographic esophageal manometry: an emerging clinical and investigative approach. Dig Dis (2000) 1.09
Exaggerated QT prolongation after cardioversion of atrial fibrillation. J Am Coll Cardiol (1999) 1.09
Systemic administration of calmodulin antagonist W-7 or protein kinase A inhibitor H-8 prevents torsade de pointes in rabbits. Circulation (1999) 1.08
A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. Clin Pharmacol Ther (2011) 1.07
Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration-response relations. Am J Cardiol (1984) 1.07
Pharmacogenomics at the tipping point: challenges and opportunities. Clin Pharmacol Ther (2011) 1.06
Distinct domains of the voltage-gated K+ channel Kv beta 1.3 beta-subunit affect voltage-dependent gating. Am J Physiol (1998) 1.06
Drug block of I(kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol (2001) 1.05
Epidemiology of endemic viral hepatitis in an urban area of India: a retrospective community study in Alwar. Bull World Health Organ (1997) 1.05
K+ currents and K+ channel mRNA in cultured atrial cardiac myocytes (AT-1 cells). Circ Res (1994) 1.05
Stereoselective disposition and pharmacologic activity of propafenone enantiomers. Circulation (1989) 1.04
Novel KCNQ1 mutations associated with recessive and dominant congenital long QT syndromes: evidence for variable hearing phenotype associated with R518X. Hum Mutat (2000) 1.04
Class III antiarrhythmic effects of zatebradine. Time-, state-, use-, and voltage-dependent block of hKv1.5 channels. Circulation (1996) 1.04
Inhibition of in vitro immune responses by a fraction from seminal plasma. Scand J Immunol (1976) 1.03
Block of human cardiac Kv1.5 channels by loratadine: voltage-, time- and use-dependent block at concentrations above therapeutic levels. Cardiovasc Res (1997) 1.03
Medication-induced esophageal injury: survey of the literature. Am J Gastroenterol (1987) 1.02
Effects of low potassium or magnesium concentrations on isolated cardiac tissue. Am J Med (1987) 1.02
Influence of genetic polymorphism on the metabolism and disposition of encainide in man. J Pharmacol Exp Ther (1984) 1.02
Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Pharmacogenomics J (2012) 1.00
Molecular determinants of stereoselective bupivacaine block of hKv1.5 channels. Circ Res (1997) 1.00
Effects of antiarrhythmic drugs on cloned cardiac voltage-gated potassium channels expressed in Xenopus oocytes. Naunyn Schmiedebergs Arch Pharmacol (2000) 0.98
Quinidine delays IK activation in guinea pig ventricular myocytes. Circ Res (1988) 0.98
Polymorphisms in the cardiac sodium channel promoter displaying variant in vitro expression activity. Eur J Hum Genet (2007) 0.97
Anti-minK antisense decreases the amplitude of the rapidly activating cardiac delayed rectifier K+ current. Circ Res (1995) 0.96
Functional expression of an inactivating potassium channel (Kv4.3) in a mammalian cell line. Cardiovasc Res (1999) 0.96
The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med (1990) 0.96
Block of IKs, the slow component of the delayed rectifier K+ current, by the diuretic agent indapamide in guinea pig myocytes. Circ Res (1994) 0.95
Functional expression of an inactivating potassium channel cloned from human heart. Circ Res (1992) 0.95
Evidence for multiple open and inactivated states of the hKv1.5 delayed rectifier. Biophys J (1998) 0.95
Suppression of repolarization-related arrhythmias in vitro and in vivo by low-dose potassium channel activators. Circulation (1990) 0.94
Cerebrovascular disease in young individuals below the age of 40 years. Neurol India (1973) 0.94